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The aim of this study was to set up a method for
quantification of plasma mitomycin C (MMC) concen-
trations during intravesical chemotherapy delivered in
the presence of local bladder hyperthermia (HT). In
comparison with existing methods, this assay, character-
ized by relative simplicity and efficiency, resulted in the
facilitation of performance with nondedicated instru-
mentation or nonspecialized staff. Purification from
plasma matrix was carried out by solid-phase extraction
under vacuum. The purified drug was then collected
directly into the vials of the HPLC autosampler. Chro-
matographic analysis was performed on a reversed-
phase C18 column with water:acetonitrile (85:15 by vol)
as the mobile phase and the UV detector set at 365 nm.
The use of porfiromycin as internal standard provided a
method with good within-day precision (CV 6.0% at 5
mg/L, n 5 6), linearity (0.5–50 mg/L), and specificity. The
lower limit of detection (<0.5 mg/L) proved to be suit-
able for plasma pharmacokinetics monitoring in two
tested patients treated with MMC1HT for superficial
bladder cancer.
INDEXING TERMS: plasma assay • bladder hyperthermia •
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Mitomycin C [aziridine(29,39:3,4) pyrrole (1, 2-a) indol-4,
7-dione-6-amino-1,1a,2,8,8a,8b-exahydro-8-(hydroxymethyl)
8a-metoxy-5-methylcarbamate] (MMC) is an antimicrobial and
anticancer agent that was isolated in 1958 from the fermenta-
tion fluid culture medium of Streptomyces caespitosus [1].2 Since
then, several clinical trials involving MMC as a single agent or
in combination with other chemotherapeutic drugs and with
different dosage schedules have been reported [2]. The most
significant MMC toxicity in humans is myelosuppression,
widely confirmed to be a delayed and dose-related effect [3].
Anemia, hepatotoxicity, and renal failure, although unusual,
have also been well documented. One of the most peculiar
MMC administration routes is intravesical instillation as a
preventive therapy for the recurrence and stage progression of
superficial bladder cancer after transurethral resection. Intra-
vesical administration has resulted in extremely low serum
concentrations, thus with virtually no systemic side effects
[4, 5]. Several investigations [6] have clearly evidenced a syn-
ergistic interaction between local increase of tumor tempera-
ture and anticancer agents’ tumoral cell killing capacity. In our
Institute, a new system (SBTS-101®) designed to simul-
taneously deliver local bladder hyperthermia (HT) and
intravesical chemotherapy (ICT) has been recently de-
veloped and clinically tested on recurrent superficial
transitional cell carcinoma of the bladder (STCCB)
[7, 8]. Preliminary results [9] were suggestive of a better
effectiveness of microwave-induced HT combined with
local chemotherapy in respect to chemotherapy alone.
However, the question is whether temperature en-
hancement of bladder mucosa could potentially affect
the systemic absorption of the cytostatic drug, render-
ing important the monitoring of plasma concentration–
time profile during ICT1HT treatment.
To quantify MMC in biological fluids, a wide number
of different analytical methods have been applied on the
basis of microbiological [10], immunological [11], and
chromatographic (HPLC) procedures [12–17]. None of the
aforementioned methods, however, completely presented
the characteristics of sensitivity (,0.5 mg/L), precision,
rapidity, and simplicity ideally required. Our aim was to
develop a low-cost HPLC assay for MMC determination
in serum that could be easily transferred to the routine
laboratory and, therefore, also carried out by nonspecial-
ized personnel and without dedicated or unusual instru-
mentation.
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The organic solvents (HPLC grade) were obtained from
J.T. Baker (Deventer, The Netherlands). Bidistilled water
was used throughout the study.
calibration solutions and calibrators
As calibrator MMC, Mitomycin-C® (injectable powder at
4% purity in NaCl) from Kyowa Hakko Kogyo (Tokyo,
Japan) was used. As internal standard, porfiromycin
(PFM) was synthesized in Japan (.99% pure) and kindly
donated by Kyowa Hakko Kogyo. MMC and PFM stock
solutions were prepared at 1.72 mmol/L (0.5 g/L) and
2.87 mmol/L (1 g/L) in methanol, respectively. These
solutions were stored at 220 °C for up to 1 month without
notable degradation. MMC working solution was 3.44
and 1.72 mmol/L (1 and 0.5 mg/L) in water, whereas PFM
was 2.87 mmol/L (1 mg/L) in 2 mol/L PBS (potassium
phosphate buffer), pH 7.4. New working solutions were
freshly prepared for dilution of the stocks at each analyt-
ical series. For unknown sample measurement, calibrators
in plasma were prepared at three different MMC concen-
trations (1, 5, 20 mg/L) and treated as described below in
the sample extraction procedure.
apparatus
Chromatographic analysis was carried out on a C18 col-
umn (Ultrasphere 150 3 4.6 mm, 5 mm; Beckman, Palo
Alto, CA) connected to a Kontron chromatographic sys-
tem (Kontron, Zurich, Switzerland) equipped with two
pumps (Model 420), an autosampler (Model 460), a dou-
ble-beam UV detector (Model 430) set at 365 nm, and a
Data System 450. The mobile phase of water:acetonitrile
(85:15 by vol) was delivered at 1.0 mL/min.
sample preparation and storage
As a preliminary study, we evaluated MMC systemic
absorption in two patients with STCCB in which MMC
instillation was associated with microwave-induced local
HT (homogeneous heating of bladder mucosa within a
medium temperature of 42.5 °C–46.5 °C). A total amount
of 40 mg of MMC was administered in 60 min but, to
avoid the drug degradation throughout the entire proce-
dure, the dose was delivered with two 30-min instillations
of 20 mg/50 mL bidistilled water. The procedure followed
in this study was in accordance with the ethical standards
of our Institution’s responsible committee.
Blood samples were taken into heparinized tubes be-
fore and every 15 min during the 60-min instillation. As
soon as possible, plasma was obtained and stored at
220 °C until analysis took place.
sample extraction procedure
After thawing and avoiding any exposure to light, plasma
samples (1 mL) were added to the internal standard PFM
(50 mL 5 50 ng) and diluted 1:1 (by vol) with water. For
solid-phase extraction, 1-mL Supelclean extraction tubes
filled with 100 mg of LC-18 end-capped sorbent were
used (Supelco, Bellefonte, PA). The disposable tubes were
connected to the Visiprep Solid Phase Extraction Vacuum
Manifolds (Supelco) and, after vacuum application with a
water pump, preactivated by washing with 2 mL of
methanol followed by 2 mL of water. The vacuum was
then disconnected to prevent the columns from drying,
the diluted plasma samples were loaded, and the vacuum
was applied again, not exceeding the flow rate of ;1
mL/min. The C18 columns were washed with water (2 3
1-mL aliquots), followed by water:methanol 90:10 (1 mL)
and water:methanol 70:30 (0.2 mL) mixtures. Columns
were completely dried by flushing air for 1–3 min; then
the vacuum was disconnected and the 12-mL polypro-
pylene tubes used to collect washings were discharged
and replaced with the 0.5-mL polypropylene microvials of
the HPLC autosampler. MMC was eluted under vacuum
with 2 3 200-mL fractions of water:methanol 50:50. The
vials were directly positioned into the sample tray of the




Under the conditions described in Materials and Methods,
the MMC and PFM showed a Rt of 4.9 and 7.2 min,
respectively, with a total analysis time of 10 min. In Fig.
1A, the chromatogram of a blank plasma sample enriched
with MMC (20 mg/L) and PFM (50 mg/L) before solid-
phase extraction is shown, whereas in Fig. 1B and C the
same control plasma was supplemented with 2.5 and 0.5
Fig. 1. Chromatographic separation of plasma samples purified by
solid-phase extraction as described in Materials and Methods.
(A) Control plasma (1 mL) supplemented with 20 ng of MMC and 50 ng of PFM;
100 mL/400 mL eluted from the C18 cartridges injected > 5 ng of MMC. (B)
Control plasma supplemented with 2.5 ng of MMC; 100 mL/400 mL injected >
0.6 ng. (C) Control plasma (1 mL) supplemented with 0.5 ng of MMC. The sample
eluted from the C18 disposable cartridge was reduced by nitrogen evaporation for
a few minutes to ;250–300 mL and 200 mL was injected into the HPLC column.
(D) Plasma taken 30 min after ICT1HT treatment (heating at 46.5 °C) from a
patient with superficial bladder cancer. The MMC peak corresponds to 5.4 mg/L.
Arrows indicate MMC (Rt 5 4.9 min) and PFM (Rt 5 7.2 min), respectively.
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mg/L MMC, respectively. In Fig. 1D, the analysis of a
serum sample taken from a patient after a 60-min instil-
lation with MMC and homogeneous heating of the blad-
der walls at 46.5 °C is shown.
We found that the length of the chromatographic
separation could be properly reduced to only 3 min (1.9
and 2.7 min Rt of MMC and PFM, respectively) simply by
replacing the 15-cm C18 column with a 3 cm 3 3 mm 3 3
mm C18 column (Supelco) (data not shown). Because of the
rapidity of the preanalytical phase, however, we consid-
ered the analysis length of 10 min acceptable for our
purpose, and we preferred the use of the 15-cm column,
thus reducing the possibility of chromatographic interfer-
ences and improving the specificity of the separation.
analytical variables
The use of PFM as the internal standard ensured good
reproducibility of the entire procedure. The extraction
efficiency and reproducibility of MMC and PFM from the
C18 columns were assessed in triplicate on plasma sam-
ples supplemented with 50 mg/L of the internal standard
PFM and with MMC (50, 20, and 5 mg/L). MMC recovery
was 98% 6 4.0%, 92% 6 6.0%, and 89% 6 7.1% at the three
concentrations tested, respectively, whereas PFM showed
a mean recovery of 85.0% 6 6.1% (n 5 9). The interference
study was carried out with caffeine, theophylline, ampho-
tericin B, epirubicin, ampicillin, amikacin, cefazolin, and
ceftriaxone. None of these commonly administered drugs
was detected under the analytical conditions used for
MMC assay. The intraday precision of the method (CV)
calculated on the MMC/PFM area ratio gave 5.8% (n 5 6)
and 6.0% (n 5 6) at 10 and 5 mg/L, respectively. The
reproducibility of the method calculated within 1 year
showed a CV of 10.7% and 9.5% for the 10 and 5 mg/L
concentrations (n 5 10), respectively. Linearity of the
assay was assessed by supplementing human control
plasma in the 0.5–50 mg/L concentration range. Linear
regression of the area ratio (y) vs MMC plasma concen-
tration expressed in mg/L (x) gave the equation y 5
0.0108(60.0001)x 1 0.005(60.003), r 5 0.999, Syux 5 0.0072.
By injecting 0.5 mg/L directly after solid-phase extraction,
the MMC signal was still evaluable with a peak area of
0.011 mVmin. To achieve a better response at this concen-
tration, avoiding larger injection volumes, we reduced the
methanol fraction of the sample by subjecting it to nitro-
gen evaporation for few minutes before HPLC injection,
thus potentially improving the detection limit (Fig. 1C).
Control plasma showed no peaks at the Rt of the two
drugs.
mitomycin c pharmacokinetics
The plasma pharmacokinetics concentration profiles re-
corded in two patients when an intravesical dose of MMC
(20 mg/50 mL replaced after a 30-min instillation) was
given in the presence of adjuvant local HT are shown in
Fig. 2. In both patients, the curves reached the maximum
peak of MMC plasma concentration between 45 and 60
min of instillation, with concentrations from 1.2 to 5.9
mg/L in the first patient and a slightly more increased
systemic absorption in the second one (plasma concentra-
tion 8.1–13.3 mg/L).
Discussion
The method set up for MMC quantification was suitable
for monitoring the kinetics of absorption in plasma during
ICT associated with local HT.
The chosen chromatographic conditions were the same
as those described by Tjaden et al. [16], but without
buffering the mobile phase because we were interested in
MMC determination only. Those authors obtained a fully
automated analysis with a continuous-flow system and a
valve-switching technique coupled to a 100 3 3 mm C8
HPLC column. Although feasible for a routine working
load, this assay procedure needed dedicated instrumen-
tation with nonstandard chromatographic apparatus and
.2 mL of plasma to reach a MMC sensitivity of ,1 mg/L.
Den Hartigh et al. [12] used a liquid–liquid extraction
with chloroform:2-propanol (1:1 by vol), whereas Dalton
et al. [17] used ethyl acetate alone. Despite the very high
solvent:sample ratio used by these authors (1:10 by vol),
and the very critical step of the solvent drying up under
reduced pressure or nitrogen and thus causing MMC
decomposition and affecting the recovery rate, this kind
of procedure appeared unsuitable for a clinical chemistry
laboratory where air exhausters and (or) equipment for
solvent evaporation are not always easily available. More-
over, the chromatographic separation of the ethyl acetate
extract shown by Dalton et al. [17], although referring to
only 1 ng of MMC injected, appears contaminated and full
of potentially interfering peaks. The use of solid-phase
extraction for MMC purification from serum has already
been reported [13, 14]. However, Tjaden et al. [13] used
homemade Amberlite XAD-2 columns requiring high
Fig. 2. Plasma pharmacokinetics absorption of MMC after ICT1HT.
The bladder cavity was filled for 60 min with MMC (20 mg/50 mL of distilled
water). After 30 min the bladder was emptied and the solution replaced with a
fresh one. The curves refer to two different patients.
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washing and elution volumes, with a drying step of the
purified methanol extract (6 mL) before HPLC analysis.
The main feature of our proposed assay consists of the
solid-phase extraction under vacuum of 1 mL of sample
with commercially available 100-mg disposable columns,
which assures a reproducible performance, avoids the use
of conspicuous extraction volumes, and allows the direct
injection of the sample eluted in the last purification step.
The chromatographic analysis does not require a dedi-
cated apparatus [16] or an unusual detector [13], so MMC
analysis can be easily scheduled on the same HPLC
apparatus used for other routine assays (drugs or metab-
olites). In addition, the manual preanalytical purification
can be fully automated with ASPEC (Gilson, Villiers Le
Bel, France) equipment for automated column extraction
directly linked to the HPLC system. The manual handling
of the purification procedure allows the simultaneous
cleanup of 12 samples every 15 min, with the use of ,3
mL of solvent and a quite low cost analysis (,$1 includ-
ing the column and the extraction eluents).
The pharmacokinetics curves reported here are only
preliminary results of a larger trial in which the effects of
local HT when associated with ICT will be thoroughly
investigated. Moreover, any eventual relation between
temperature delivered during the hyperthermic treatment
and the systemic absorption of the drug is presently
under careful examination.
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